Format

Send to

Choose Destination
Antiviral Res. 2018 Jun;154:58-65. doi: 10.1016/j.antiviral.2018.04.011. Epub 2018 Apr 14.

Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers.

Author information

1
Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, 930-0194, Japan.
2
Department of Biomedical Engineering, Faculty of Biology-Oriented Science and Technology, Kindai University, Kinokawa, Wakayama, 649-6493, Japan. Electronic address: masaki@waka.kindai.ac.jp.
3
Kanagawa Prefectural Institute of Public Health, Chigasaki, Kanagawa, 253-0087, Japan.
4
Department of Virology, Osaka Prefectural Institute of Public Health, Osaka, 537-0025, Japan.
5
BIKEN Endowed Department of Dengue Vaccine Development, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, 565-0871, Japan; BIKEN Endowed Department of Dengue Vaccine Development, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand.
6
Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, 930-0194, Japan. Electronic address: immkishi@med.u-toyama.ac.jp.

Abstract

West Nile virus (WNV) is a positive-sense single-stranded RNA flavivirus belonging to the Japanese encephalitis virus (JEV) serocomplex of the Flaviviridae family and causes mosquito-borne infections. Although most human infection cases are asymptomatic, approximately one in 150 infected individuals develops meningoencephalitis, with a mortality rate of 4-14%. While the development of human neutralizing antibody therapeutics against WNV is strongly anticipated, WNV is difficult to study in conventional laboratories due to its high safety level requirement. In this study, we established fully human WNV-neutralizing monoclonal antibodies from the peripheral blood mononuclear cells of inactivated-JEV-vaccinated individuals, and these antibodies exhibited WNV neutralization both in vitro and in vivo. Our results demonstrate a new antibody cross-reactivity strategy to develop immunological therapeutic reagents for WNV and other JEV serotype viruses.

KEYWORDS:

Human monoclonal antibody; Japanese encephalitis virus; Neutralization antibody; Vaccination; West Nile virus

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center